birb 796 has been researched along with Acute Lymphoid Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelmann, I; Brümmendorf, TH; Kharabi Masouleh, B; Patterson, JB; Preisinger, C; Salimi, A; Samali, A; Schemionek, M; Vieri, M | 1 |
1 other study(ies) available for birb 796 and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzopyrans; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synergism; Endoribonucleases; Fusion Proteins, bcr-abl; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice, Transgenic; Morpholines; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Cell Culture; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Pyrimidines; Synthetic Lethal Mutations; X-Box Binding Protein 1 | 2021 |